Zirabev Coupon & Prices

Is your Zirabev medication too expensive?

Get notified when Zirabev medication becomes available.

Get Started Now
Medically reviewed by  Jamie Winn, PharmD

Your monthly Zirabev cost savings if eligible

With our assistance, you could access the Zirabev patient assistance program and obtain your medication for free. We only charge a flat monthly fee of $49 per medication for our services.

Am I eligible for Zirabev patient assistance?

We review each Zirabev enrollment application individually to determine if you are eligible. Each assistance program has its own eligibility criteria and the factors considered by most programs are:

  • I am a permanent, legal resident of the United States or Puerto Rico
  • I am uninsured or my insurance doesn’t cover my medication
  • I meet certain income eligibility requirements

How do I apply for the Zirabev patient assistance program?

Our process makes it as easy as possible to apply for the Zirabev patient assistance program. Begin by completing the enrollment application form on our website. Tell us about any medications that you are taking, including Zirabev, your healthcare provider, your insurance plan, and your household income. This information is required by the pharmaceutical manufacturers who will supply the medication, so it is important to make sure this information is accurate and up to date.

We will review the information that you have provided to determine whether you are eligible for patient assistance. If we can pre-qualify you for assistance, NiceRx will handle the full enrollment process on your behalf. If you are approved by the pharmaceutical company, you will typically start receiving your medication in 6 – 8 weeks.

Is NiceRx a Zirabev coupons provider?

NiceRx is not a Zirabev coupon, Zirabev discount card, or Zirabev copay card provider. We do not offer Zirabev manufacturer coupons, Zirabev discounts, rebates, Zirabev savings cards, trial offers, or free Zirabev samples. We are a service provider that helps eligible individuals access their medication directly from the U.S. pharmaceutical company.

Can NiceRx help me if I have insurance?

NiceRx may be able to help you if:

  • You have a high copay or coinsurance responsibility for Zirabev
  • Your insurance company will not pay for your Zirabev prescription
  • Your healthcare plan does not cover your medication
  • You do not have insurance

Please apply online to find out if we can help you.

How much does Zirabev cost without insurance?

Without insurance, Zirabev costs will vary depending on where you buy the medication as prices will vary by retailer. As a guide, Zirabev intravenous solution (bvzr 25 mg/mL) will cost around $650 for a supply of 4 milliliters, depending on the pharmacy you visit.

How much does Zirabev cost with insurance?

The copay for Zirabev will depend on the terms of your healthcare plan. Your healthcare provider or pharmacist will be able to calculate your copay with your current insurance. Contact them to find out more.

What is Zirabev?

Zirabev is an FDA-approved medication manufactured by Pfizer Inc., for patients above 18 years of age. Zirabev (bevacizumab-bvzr), a biosimilar to Avastin® (bevacizumab). It is indicated for use in patients with the following types of cancer:

Metastatic Colorectal Cancer (mCRC)

  • First- or second-line treatment in combination with intravenous fluorouracil-based chemotherapy
  • Second-line treatment when used with fluoropyrimidine-based (combined with irinotecan or oxaliplatin) chemotherapy after cancer progresses following a first-line treatment that includes a bevacizumab product
  • Zirabev is not approved for use after the primary treatment of colon cancer that has not spread to other parts of the body

Non-Small Cell Lung Cancer (NSCLC)

  • Zirabev, in combination with carboplatin and paclitaxel, is approved to treat advanced non-squamous NSCLC in people who have not received chemotherapy for their advanced disease

Recurrent Glioblastoma (GBM)

  • Zirabev is approved to treat GBM in adult patients whose cancer has progressed after prior treatment (recurrent or rGBM)

Metastatic Renal Cell Carcinoma (mRCC)

  • Zirabev, used with interferon alfa, is approved to treat mRCC

Advanced Cervical Cancer (CC)

  • Zirabev, in combination with paclitaxel and cisplatin or paclitaxel and topotecan, is approved to treat persistent, recurrent, or metastatic cancer of the cervix

Ovarian Cancer (OC)

Zirabev is approved to treat epithelial ovarian, fallopian tube, or primary peritoneal cancer:

  • In combination with carboplatin and paclitaxel, followed by Zirabev alone, for the treatment of patients with advanced (stage III or IV) disease following initial surgery
  • In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, for platinum-resistant recurrent disease in women who received no more than 2 prior chemotherapy treatments
  • Either in combination with carboplatin and paclitaxel or with carboplatin and gemcitabine, followed by Zirabev alone, for patients with platinum-sensitive recurrent disease

What doses of Zirabev are available?

Zirabev (bevacizumab-bvzr) is available as a single-dose vial for intravenous use.  It is a sterile, preservative-free and available in the following presentation: 100 mg/4 mL (25 mg/mL) or 400 mg/16 mL (25 mg/mL). It is clear to slightly opalescent, colorless to a pale brown solution.

Each mL of solution contains 25 mg bevacizumab-bvzr, edetate disodium dihydrate (0.05 mg), polysorbate 80 (0.2 mg), succinic acid (2.36 mg), sucrose (85 mg), and Water for Injection, USP. The pH is 5.5.

Always speak with your healthcare provider about any changes to your dose so they can monitor and evaluate your condition.

Zirabev active ingredients

ZIRABEV contains bevacizumab-bvzr. Bevacizumab-bvzr is a vascular endothelial growth factor inhibitor. Bevacizumab-bvzr is a recombinant humanized monoclonal IgG1 antibody that contains human framework regions and murine complementarity-determining regions. Bevacizumab-bvzr has an approximate molecular weight of 149 kDa. Bevacizumab-bvzr is produced in a mammalian cell (Chinese Hamster Ovary) expression system.

Zirabev dosage and administration are dependent on the indication. Regardless of indication, Zirabev cannot be administered until at least 28 days following surgery and resultant wound healing.

Zirabev side effects

The most common side effects or adverse reactions caused by Zirabev include:

  • High blood pressure (hypertension)
  • Too much protein in the urine
  • Nosebleeds
  • Bleeding
  • Back pain
  • Headache
  • Taste change
  • Dry skin
  • Inflammation of the skin
  • Inflammation of the nose
  • Watery eyes

In rare instances, Zirabev can cause more serious side effects. These can be fatal and include:

  • GI perforation. A hole that develops in your stomach or intestine. Symptoms include pain in your abdomen, nausea, vomiting, constipation, or fever
  • Wounds that don’t heal. A cut made during surgery can be slow to heal or may not fully heal. Do not undergo surgery without first discussing this potential risk with your doctor
  • Serious bleeding. This includes vomiting or coughing up blood; bleeding in the stomach, brain, or spinal cord; nosebleeds; and vaginal bleeding. If you recently coughed up blood or had serious bleeding, be sure to tell your doctor

Other possible side effects include:

  • Abnormal passage in the body. This type of passage—known as a fistula—is an irregular connection from one part of the body to another and can sometimes be fatal
  • Severe high blood pressure. Blood pressure that severely spikes or shows signs of affecting the brain. Blood pressure should be monitored every 2 to 3 weeks while on ZIRABEV and after stopping treatment
  • Kidney problems. These may be caused by too much protein in the urine and can sometimes be fatal
  • Infusion-related reactions. These were uncommon with the first dose of bevacizumab (less than 3% of patients); 0.4% of patients had severe reactions. Infusion reactions include high blood pressure or severe high blood pressure that may lead to stroke, trouble breathing, decreased oxygen in red blood cells, a serious allergic reaction, chest pain, headache, tremors, and excessive sweating. Your doctor or nurse will monitor you for signs of infusion reactions
  • Severe stroke or heart problems. These may include blood clots, mini-stroke, heart attack, chest pain, and your heart may become too weak to pump blood to other parts of your body (congestive heart failure). These can sometimes be fatal
  • Nervous system and vision problems. Signs include headache, seizure, high blood pressure, sluggishness, confusion, and blindness

Your doctor will assess the benefits of using Zirabev against your risk of side effects. To report SUSPECTED ADVERSE REACTIONS, contact Pfizer, Inc. at
1-800-438-1985 and or FDA at 1-800-FDA-1088 or

Zirabev drug interactions

Zirabev can interact with other medications. These include:

  • alendronate
  • deferiprone
  • etidronate
  • filgrastim
  • ibandronate
  • idelalisib
  • palifermin
  • pamidronate
  • panitumumab
  • pegfilgrastim
  • radium 223 dichloride
  • risedronate
  • romosozumab
  • samarium sm 153 lexidronam
  • sargramostim
  • sodium phosphate p32
  • strontium-89 chloride
  • sunitinib
  • tbo-filgrastim
  • thalidomide
  • tiludronate
  • topotecan
  • zoledronic acid

There are 7 disease interactions:

  • fistula formation
  • GI perforation
  • bleeding
  • hypertension
  • PRES
  • proteinuria
  • thromboembolic disorders

This list is not exhaustive and other drugs may interact with Zirabev.

Zirabev contraindications

  • Gastrointestinal Perforations and Fistula: Discontinue for gastrointestinal
    perforations, tracheoesophageal fistula, grade 4 fistula, or fistula
    formation involving any organ
  • Surgery and Wound Healing Complications: Discontinue in patients who
    develop wound healing complications that require medical intervention or
    necrotizing fasciitis.  Withhold for at least 28 days prior to elective
    surgery.  Do not administer Zirabev for at least 28 days after surgery,
    and until the wound is fully healed
  • Hemorrhage: Severe or fatal hemorrhages have occurred. Do not administer for recent hemoptysis. Discontinue for Grade 3-4 hemorrhage
  • Arterial Thromboembolic Events (ATE): Discontinue for severe ATE
  • Venous Thromboembolic Events (VTE): Discontinue for Grade 4 VTE
  • Hypertension: Monitor blood pressure and treat hypertension. Withhold if
    not medically controlled; resume once controlled. Discontinue for hypertensive crisis or hypertensive encephalopathy
  • Posterior Reversible Encephalopathy Syndrome (PRES): Discontinue
  • Renal Injury and Proteinuria: Monitor urine protein. Discontinue for
    nephrotic syndrome. Withhold until less than 2 grams of protein in the urine
  • Infusion–Related Reactions: Decrease rate for infusion-related reactions.  Discontinue for severe infusion-related reactions and administer medical
  • Embryo-Fetal Toxicity: May cause fetal harm. Advise females of the potential risk to fetus and need for use of effective contraception
  • Ovarian Failure: Advise females of the potential risk
  • Congestive Heart Failure (CHF): Discontinue ZIRABEV in patients who
    develop CHF

You should not use Zirabev if you:

  • Are allergic to the active ingredient Zirabev
  • Are allergic to any of the other ingredients in Zirabev
  • Are pregnant or are planning to become pregnant

Talk to your doctor before using Zirabev if you:

  • Are taking any of the medications that could interact with Zirabev
  • Are breastfeeding or are planning to breastfeed

Zirabev generic

Zirabev is the trademark brand name for bevacizumab-bvzr manufactured by Pfizer inc. A generic version of Zirabev is not available. Generic drugs are generally cheaper than brand-name drugs, but you can still find Zirabev savings through NiceRx.

The content on this website is intended for information purposes only. It does not constitute medical advice. The information on this website should not be relied upon and is not a substitute for professional medical advice. You should always speak to your doctor regarding the risks and benefits of any treatment.